Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Desjardins, Annick, Reardon, David A., Herndon, James E., Marcello, Jennifer, Quinn, Jennifer A., Rich, Jeremy N., Sathornsumetee, Sith, Gururangan, Sridharan, Sampson, John, Bailey, Leighann, Bigner, Darell D., Friedman, Allan H., Friedman, Henry S., Vredenburgh, James J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2008
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3671765/
https://ncbi.nlm.nih.gov/pubmed/18981004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0260
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge